Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy

Authors

David Wang, Department of Neurology, Petznick Stroke Center, Barrow Neurological Institute, Phoenix, Arizona, USA david.wang@commonspirit.org.Follow
Christopher Leo, Department of Medicine/Division of General Internal Medicine/Hospital Medicine, Duke University, Durham, North Carolina, USA.
Liping Liu, Neurosurgical Intensive Care Unit (NICU), Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Li Huang, Doctors Medical Center, Modesto, California, USA.
Lisa Huang, Chesapeake Regional Medical Center, Chesapeake, Virginia, USA.
Yun Lu, Hennepin Healthcare System and the University of Minnesota, Minneapolis, Minnesota, USA.

Document Type

Article

Medical Subject Headings

Humans; COVID-19; Fibrinolytic Agents (adverse effects); Anticoagulants (adverse effects); Platelet Aggregation Inhibitors (adverse effects)

Publication Date

8-1-2023

Publication Title

Stroke and vascular neurology

E-ISSN

2059-8696

Volume

8

Issue

4

First Page

263

Last Page

265

PubMed ID

36797011

Digital Object Identifier (DOI)

10.1136/svn-2023-002321

Recommended Citation

Wang, David; Leo, Christopher; Liu, Liping; Huang, Li; Huang, Lisa; and Lu, Yun, "Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy" (2023). Neurology. 1760.
https://scholar.barrowneuro.org/neurology/1760